- PLN39.11m
- PLN33.86m
- PLN22.48m
- 87
- 24
- 12
- 32
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.86 | ||
| Price to Tang. Book | 3.9 | ||
| Price to Free Cashflow | 22.31 | ||
| Price to Sales | 1.74 | ||
| EV to EBITDA | 16.5 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.93% | ||
| Return on Equity | 10.3% | ||
| Operating Margin | 6.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 19.67 | 18.75 | 19.89 | 20.46 | 22.48 | n/a | n/a | 3.87% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -33.01 | -58 | +200.29 | -72.7 | +193.38 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 30th, 2010
- Public Since
- May 30th, 2011
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 1,321,301
- Address
- ul. Ponczowa 12, WARSZAWA, 02-971
- Web
- http://www.genomed.pl
- Phone
- +48 226446019
- Auditors
- MS Rewident
Upcoming Events for GEN
Similar to GEN
Airway Medix SA
Warsaw Stock Exchange
Bioton SA
Warsaw Stock Exchange
Braster SA
Warsaw Stock Exchange
Captor Therapeutics SA
Warsaw Stock Exchange
E-Shopping SA
Warsaw Stock Exchange
FAQ
As of Today at 19:09 UTC, shares in Genomed SA are trading at PLN29.60. This share price information is delayed by 15 minutes.
Shares in Genomed SA last closed at PLN29.60 and the price had moved by -18.68% over the past 365 days. In terms of relative price strength the Genomed SA share price has underperformed the FTSE Global All Cap Index by -24.99% over the past year.
There is no consensus recommendation for this security.
Genomed SA does not currently pay a dividend.
Genomed SA does not currently pay a dividend.
Genomed SA does not currently pay a dividend.
To buy shares in Genomed SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN29.60, shares in Genomed SA had a market capitalisation of PLN39.11m.
Here are the trading details for Genomed SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: GEN
Based on an overall assessment of its quality, value and momentum Genomed SA is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genomed SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -19.88%.
As of the last closing price of PLN29.60, shares in Genomed SA were trading -16.53% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Genomed SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN29.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Genomed SA's directors